Costs, administration marketing

Indirect costs Administration, marketing, accounting, legal, insurance, office 10.10... 

Most people agree that general expenses incurred in administration, selling, distribution, etc., should not be included in the cost of inventory. In fact, many feel that no costs should be absorbed before they have been incurred. In general, method 2 is favored by engineers and method 3 by most accountants. However, the accountancy convention is to value at either cost or market value, whichever is the lower. In the methods considered, either ac tual or standard costs can be used. Note that method 3 shows a higher profit than method 2 when sales volume exceeds the produc tion rate and a lower profit when the production rate exceeds sales volume. 

Amabile, T. M., Conti, R., Coon, H., Lazenby, J., and Herron, M. (1996), Assessing the work environment for creativity," Academy of Management Journal, 39 (5), 1154-84. Ancona, D. G. and Caldwell, D. F. (1992), "Bridging the boundary External activity and performance in organizational teams," Administrative Science Quarterly, 37 (4), 634-65. Anderson, E. (1985), "The salesperson as outside agent or employee a transaction cost analysis," Marketing Science, 4 (3), 234-54. 

Pharmacologic management of thrombosis includes local administration of thrombolytic agents. Alteplase (2 mg per port) and reteplase (0.5 unit per port) are the two most commonly used agents today. Urokinase has been used in the past, but after its reintroduction to the United States market, the larger dosed vial size makes it less cost effective than the newer agents. 

Assume the retained earnings are worth 10% after taxes. (Issuing new stock has administrative costs and it must be sold for less than the market value.)... 

And third, given that regulatory intervention generates both benefits and costs, the benefits of price control might be more than cancelled out (welfare loss) by its costs in the form of administrative costs, transaction costs and distortions in incentives derived from the regulation itself.5 The costs of an imperfect market cannot be compared with those of a perfect one, and pharmaceutical price regulation failures must be taken into account. 

The time and expense required to develop new drug products are enormous. A recent public food and drug administration (FDA) report (1) estimates that the cost of bringing a new drug to market is between 800 million to 1.7 billion, which represents a 50% increase in just five years (Fig. 1). This cost escalation has very substantial consequences The number of new drugs and devices submitted to the FDA is dropping rapidly and today it is less than half the number submitted five years ago (Fig. 2). Because of these rising... 

One of the main drivers for the development of new pulmonary drug delivery systems has been the potential for noninvasive systemic delivery of protein and peptide compounds. The systemic delivery of macromolecules via the airways would overcome the inconvenience and cost associated with current methods of administration (injection), and appears likely given the large surface area of the airways and the thin pulmonary epithelium. Most research has concentrated on pulmonary delivery of insulin for the treatment of diabetes. Recently, one insulin product has completed phase three studies and is now undergoing review by European regulatory agencies for marketing approval. 

The USEPA has estimated that the market value for remediation of non-federal facilities is 6.7 billion (1996 dollars). This estimated cost does not include costs for site assessment and studies, design, operation and maintenance, long-term responses, site management, administrative cost, other agency support, oversight of potentially responsible parties (PRPs), and enforcement activities. The estimate was based on the assumption that PRPs will be responsible for at least 70% of the cost. 

Allen Clamen For example, there is no allocation of marketing and administrative cost. We learned a long time ago that this is something we didn t want to get in to. There is a base cost of running the business that doesn t enter in to the cost of developing new products. 

---